Drugs / JLM019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07623850 | Jan 2026 → Mar 2029 expected | Hodgkins lymphoma, non-Hodgkin lymphoma | Jecho Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-20 | Jecho Biopharmaceuticals Co., Ltd. | Major Milestone Announced: Jechobio JLM019 Injection Completes First Patient Dosing in Clinical Trial for Advanced Malignant Tumors jechobio.com ↗ |
| 2025-12-01 | Jecho Biopharmaceuticals Co., Ltd. | Jechobio’s JLM019 Program Selected for Tianjin Municipal Major Biomedical Science and Technology Special Project jechobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JLM019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623850 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” NCT07623850 ↗ |